Progress in Neuro-Psychopharmacology & Biological Psychiatry 1991: Vol 15 Index

9 Pages·1991·1.6 MB·English

SUBJECT INDEX
Abecarnil, anxiolytic properties 207 Alcohol withdrawal, GABA 921-934
Abstract thinking, Alzheimer’s disease 465 Alpidem, anxiolytic properties 207
Acetylcholine, synthesis and release in Alzheimer’s disease
hippocampus, nerve growth factor 853, 856 arecoline 643-648
N-Acetylserotonin, pineal, clorgyline and age 897 cytokines 490
Acoustic startle reflex, opiate-dopamine early detection battery for dementia 433-479
interactions 415-426 clinical diagnosis 437
Addiction treatment, buprenorphine 531-538 cognitive assessment battery 445-466
Adenosine-3’ ,5’-monophosphate, magnetic resonance imaging 586
neurotensin-sensitive protein nerve growth factor 163, 858
phosphorylation 87 Amineptine, leukocyte B-adrenoceptors 357-367
Adenylate cyclase 1-Aminocyclopropanecarboxylic acid, anxiolytic
5-HT,, receptor interaction 741 action 751
lithium and antidepressants 709-716 Amitriptyline
Adrafinil, motor activity 833 5-HT,, responsivity 731
Adrenal gland prophylactic efficacy 71-82
function in abstinent alcoholic men 771-780 supersensitivity to hypothermic effects of
phenelzine methyltransferase 308 oxotremorine and nicotine 540, 544
a-Adrenergic receptors, motor activity 825-840 Amphetamine
B-Adrenergic receptors acoustic startle reflex 419
leukocytes, amineptine 357-367 conditioning 841-850
pineal gland 898 induced behaviours, effect of 5-HT
Adrenocorticotropic hormone depletion 105-117
abstinent alcoholic men 771-780 Amphetamine-haloperidol, motor activity 910
fast feedback regulation by cortisol 523-529 B-Amyloid precursor protein, interleukin-6 490
fenfluramine and dexamethasone 639, 641 Androgens, dopaminergic function 263
D-fenfluramine response in depression 785 Animal models
ipsapirone response, anxiety and anxiety 205-212
depression 725-731 anxiolytics, infant separation 745-757
Affective disorders attention deficit hyperactivity disorder 129
cholinergic properties of drugs 545 behaviour, noradrenergic system 825-840
corticotropin releasing hormone 380 depression 199-204
genetic databases 173 role of S-HT 735-744
lithium administration by eye drops 315-321 tardive dyskinesia, diltiazem 717-722
magnetic resonance imaging 584, 585 Anorexia
Age, monoamine metabolites in plasma 507 corticotropin releasing hormone 379-391
Aggression, phenylacetic acid in plasma 145 mood 15-23
Aging pituitary abnormalities 351-356
dietary choline and behaviour 677-688 Anterior hypothalamic—preoptic area, muscarinic
glycosaminoglycan polysulfate in receptors and locomotion 279-284
dementias 323-342 Anticonvulsants, 2-propyl-l-aminopentane and
melatonin synthesis 561-566 2-((2-propyl)pentylamino)
MAO.-A inhibitor 896-900 acetamide 303-306
memory 435 Antidepressants
nerve growth factor 161 blockade of 5-HTP induced depression 738
Agnosia, Alzheimer’s disease 459 forskolin binding in brain 709-716
AIDS 5-HT induced PI response 393-403
peptide T pharmacokinetics 791-801 leukocyte B-adrenoceptors 357-367
SPECT scanning, dementia 650 mechanisms of action 739
Akathisia, neuroleptics 223 metabolism in rat 285-289
Alcohol, antagonism by ganglioside and sialic olfactory bulbectomy model 202
acid 91-104 orthostatic hypotension 64, 66, 68
Alcoholism, adrenal function during pineal melatonin synthesis 895-902
abstinence 771-780 prophylactic efficacy 71-82
xii Subject Index
psychotic depression 765-770 Bretazenil, anxiolytic properties 207
schizophrenia 2-6 Bromocriptine, effect on nucleus accumbens
schizophrenic substance abuse 7-9 neurons 122
simulated home treatment of depression 63-70 BRON, abuse of 513-521
thyroid hormones 596 Bulimia, pituitary abnormalities 351-356
Anxiety Buprenorphine, treatment of heroin
animal models 205-212, 745-757 dependence 531-538
ethanol and ganglioside 93, 95 Buspirone, animal models of anxiety 209, 749
ethanol withdrawal, GABA 922, 930
5-HT,, receptors 723-733
magnetic resonance imaging 587 Caerulein, hypnogenic action 817
Anxiolytic drugs Caffeine, in BRON 513-521
animal models 205-212 Calcium, neurotensin-sensitive protein
infant rat separation test 745-757 phosphorylation 85
Apomorphine Calcium channel inhibitors
acoustic startle reflex 419 haloperidol-induced dopaminergic
growth hormone response, effect of supersensitivity 718, 719
methyltestosterone 263-268 schizophrenia 343
induced behaviours, effect of 5-HT Candidate loci, neuropsychiatric diseases 172,
depletion 105-117 174, 176
low-dose, autoreceptor activation and Carbachol, muscarinic receptors and
behavioural consequences 689-698 locomotion 279-284
Appetite suppression, corticotropin releasing Carbon dioxide, panicogenic effect 237-239
hormone 387 Carteolol, heart rate 702, 704
Arcaine 187 Cat
Arecoline, Alzheimer’s disease 643-648 5-HT depletion and apomorphine or
Arousal, depression 257 amphetamine induced behaviours 105-117
Astrocytes, interleukin-6 production 483, 485 naloxone effects on visual evoked
Atropine potentials 567-579
antagonism of physostigmine effects 875 Catecholamines, MAOI 146
carbachol and locomotion 281 Caudate nucleus, neurotensin-sensitive protein
Attention phosphorylation 83-89
Alzheimer’s disease 462 Cerebellum, in vivo modulation of
HIV-positive drug abusers 653, 655 cGMP 229-235
Attention deficit hyperactivity disorder Cerebral blood flow, SPECT, HIV 649-662
animal model 129 Cerebrospinal fluid
methylphenidate metabolism 213-220 cholecystokinin in 601-609
Auditory evoked potentials, lateralization 761 phenylacetic acid in, schizophrenia 41-47
Autoimmunity, candidate loci 175, 177 CGS 12066B, animal model of anxiety 749
Autonomic nerve dysfunction, stress 699-708 p-Chlorophenylalanine
Autoradiography, cholecystokinin binding sites in effect on apomorphine and amphetamine
brain 291-296 induced behaviours 105-117
Autoreceptors, apomorphine 689-698 5-HT induced phosphoinositide
hydrolysis 393-403
Chlorpheniramine, in BRON 513-521
Behavioural modes, a-noradrenergic Cholecystokinin
system 825-840 in CSF, psychosis and antipsychotic
Behavioural Pattern Monitor 905, 906 response 601-609
Benzodiazepine agonists, GABA modulation of food intake in undernourished rats 405-413
receptor affinity 924 panicogenic effect 237-239
Benzodiazepine receptor ligands, anxiolytic Cholecystokinin receptors, localization in brain,
properties 207 autoradiography 291-296
Benzodiazepines Choline, dietary, behavioural effects during
animal models of anxiety 748 aging 677-688
sleep 817, 821 Choline acetyltransferase, nerve growth
sodium divalproex interaction 269-273 factor 162, 163, 853, 856
thyroid hormones 596 Cholinergic function
Beta-blockers, heart rate 699-708 Alzheimer’s disease 643
Bipolar affective disorder, lithium administration nerve growth factor 851-860
by eye drops 315-321 thermoregulation 873-884
Blood group markers 177 Cholinergic neurons, nerve growth factor and
Blood pressure, nortriptyline 67 neostriatum 157-169
Body temperature, ethanol and ganglioside 93, 94 Cholinergic stimulation, locomotion 279-284
Subject Index
Circadian rhythm, adrenal function in D-fenfluramine and HPA axis
alcoholism 776 hormones 781-790
Clonidine genetic databases 173
information processing 497-502 5-HT 394, 401, 735-744
motor activity 828-838 HPA axis 637-642
Clorgyline, pineal melatonin synthesis, 5-HT;, receptors 726
aging 895-902 5-HT, receptors 49-61
Cocaine-haloperidol, motor activity 910-912 leukocyte B-adrenoceptors and amineptine
Codeine, in BRON 513-521 treatment 357-367
Cognitive functioning lithium side effects 428
Alzheimer’s disease 435 magnetic resonance imaging 584, 585, 588
assessment battery 445-466 a-methyltryptophan as a therapeutic agent 936
diagnostics 436 phenylethylamine and phenylacetic acid 144
anorexia nervosa 20 post-psychotic, TRH test 369-378
arecoline 643-648 preparatory brain potentials 257-262
elderly, glycosaminoglycan polysulfate 323-342 prophylactic efficacy of tricyclic
Conditioning with amphetamine 841-850 antidepressants 71-82
Confrontational naming, Alzheimer’s disease 450 pseudodementia 439, 463
Contingent negative variation, depression 257 psychotic, tricyclic antidepressants 765-770
Core temperature 541, 545 seasonal platelet 5-HT uptake 25-39
Cortical ablation, NMDA stimulated release of simulated home treatment with
dopamine 666, 669 nortriptyline 63-70
Corticosterone, physostigmine and substance-abusing schizophrenic patients 1-13
thermoregulation 877, 881 temporal segmentation of response
Corticotropin releasing hormone speed 249-255
anorexigenic effects in monkey 379-391 p-tyramine challenge test 241-247
induced B-endorphin release, interleukin-1 Desipramine
potentiation of 554, 557 forskolin binding in brain 709-716
response in abstinent alcoholic men 771-780 prophylactic efficacy 71-82
Cortisol Development
abstinent alcoholic men 771-780 cholecystokinin satiety in undernourished
fast feedback regulation of ACTH 523-529 rats 405-413
fenfluramine and dexamethasone 640 nerve growth factor 161
D-fenfluramine response in depression 786 somatic and behavioural, dopamine D1
ipsapirone response, anxiety and receptors 129-138
depression 725-731 Dexamethasone suppression test
Cough suppressant, BRON, abuse of 513-521 post D-fenfluramine hormone levels 786
Cytokines 482 role of S-HT in HPA axis escape 637-642
Alzheimer’s disease 490 Diabetes mellitus, autoimmunity 177, 178
potentiation of B-endorphin secretion 551-560 Diazepam
production by stimulated astrocytes 485 heart rate 702, 705
thyroid hormone changes in panic disorder 598
Diet, phenylalanine, plasma metabolites 611-623
Debrisoquine, MAO inhibition 297-301 Dihydroergotamine, migraine 192
Dementia Diltiazem, oral stereotypies 717-722
arecoline 643-648 Dissociative anaesthetics, NMDA receptor 184
early detection battery 433-479 Dog, cholecystokinin receptors in brain 291-296
assessment, organic diagnosis 437 Domperidone, effect on nucleus accumbens
cognitive assessment battery 445-466 neurons 124
screens 440 Dopamine
HIV drug abusers, SPECT 649-662 apomorphine induced hypomotility 690-698
magnetic resonance imaging 586 inhibition of nucleus accumbens neurons 122
old age, glycosaminoglycan polysulfate MAOI 146
treatment 323-342 opiate interactions in acoustic startle
Denial of illness, anorexia nervosa 15-21 reflex 415-426
Deprenyl, phenylethylamine in brain 146, 152 phenylethylamine effect on transmission 149,
Depression 152
animal models 199-204 release from nucleus accumbens, NMDA
role of S-HT 735-744 receptors 663-673
anorexia nervosa 19 turnover in brain, effects of SCH 23390 and
cholinergic properties of drugs 545 ritanserin 861-872
corticotropin releasing hormone 380 Dopamine agonists, motor behaviour 903-919
Xiv Subject Index
Dopamine antagonists GABA, ethanol withdrawal 921-934
dopamine and 5-HT turnover 861-872 Ganglioside, attenuation of intoxicating effects of
methamphetamine interaction 803-815 ethanol 91-104
Dopamine D1 receptor Genetic databases, inborn errors of
mediated inhibition of nucleus accumbens metabolism 171-181
neurons from ventral tegmental Glial cells, interleukin-6 production 483, 485
area 119-128 Glucocorticoids, thermoregulation 881
somatic and behavioural ontogeny 129-138 Glutamate
Dopamine D2 receptor mRNA, distribution in NMDA receptor 184
primate brain 885-893 stimulated dopamine release 667
Dopaminergic function, androgens 263 Glycine
Dopaminergic transmission, Ca2+ channel cerebellar cGMP 230
inhibitors 718, 720 NMDA receptor 184
Doxepin, prophylactic efficacy 71-82 Glycosaminoglycan polysulfate, treatment of old
Drug abuse, HIV, SPECT 649-662 age dementias 323-342
Dynamical entropy, dopamine and motor G proteins
behaviour 915 5-HT,, receptors 728
Dysnomia, Alzheimer’s disease 451 lithium and antidepressants 713
Dystonia, neuroleptics 222 lithium and light sensitivity in affective
disorder 317
Growth hormone, response to apomorphine, effect
Eating disorders, pituitary abnormalities 351-356 of methyltestosterone 263-268
Elderly, glycosaminoglycan polysulfate in Guanosine-3’ ,5’-monophosphate, cerebellum, in
dementias 323-342 vivo modulation 229-235
B-Endorphin
interleukin-1 potentiation of secretion 551-560
response to D-fenfluramine in depression 785 Hallucinations, BRON 518
Environmental temperature, antagonism of Haloperidol
physostigmine effects 873-884 CSF cholecystokinin and antipsychotic
Ergot compounds, migraine 192 response 605
Ethanol, antagonism by ganglioside or sialic diltiazem and oral stereotypies 717-722
acid 91-104 effect on nucleus accumbens neurons 122-126
Ethanol withdrawal, GABA 921-934 plasma levels in schizophrenics 225
Event related potentials Haloperidol-amphetamine, motor activity 910
clonidine and scopolamine 499 Haloperidol—cocaine, motor activity 910, 912
depression 251, 253 Haloperidol reductase, red blood cells 275-278
Excitatory amino acids Headache, 5-HT receptors 191-197
animal model of anxiety 750 Heart rate, beta-blockers and diazepam 699-708
in vivo modulation of CGMP 229-235 Height, monoamine metabolites in plasma 508
NMDA receptor 186 Heroin, prepulse inhibition 420, 422
Excitatory amino acid agonists, dopamine release Heroin addiction, buprenorphine 531-538
from nucleus accumbens 663-676 Hippocampus
Exploration, ethanol and ganglioside 93, 95 antidepressants and 5-HT-induced PI
Extinction learning, dietary choline 681, 683, 685 response 393-403
nerve growth factor and cholinergic
function 851-860
Fast feedback, ACTH/cortisol 523-529 HIV
Feeding behaviour peptide T 791-801
cholecystokinin 405-413 SPECT scanning, dementia 649-662
corticotropin releasing hormone 385, 386 Home treatment, depression 63-70
Fenfluramine Homovanillic acid
effect on HPA axis 639 in brain, effect of SCH 23390 and
HPA axis hormones and prolactin responses in ritanserin 864
depressed patients 781-790 in plasma, age, sex, weight and height
Flunitrazepam correlates 503-512
binding to GABA receptors during ethanol Hospitalization/home treatment, depression 63
withdrawal 924 Human gene mapping library 173
hypnotic action reversed by Huntington’s chorea, nerve growth factor 163
proglumide 817-823 Hydralazine, methylation 309
Fluoxetine, 5-HT,, responsivity 731 Hydrocortisone hemisuccinate, ACTH
Fluphenazine, schizophrenia 224 regulation 523-529
Forskolin, binding in brain, effect of lithium and 8-Hydroxy-(di-N-propylamino)tetralin, inhibition by
antidepressants 709-716 adenylate cyclase 741
Subject Index
5-Hydroxyindoleacetic acid Hypothermia
interhemispheric asymmetry in brain 761 ipsapirone induced, anxiety and
pineal, clorgyline and age 897 depression 725-731
plasma, age, sex, weight and height physostigmine induced 875
correlates 503-512
p-Hydroxyphenelzine, MAO inhibition 297-301
m-Hydroxyphenylacetic acid, plasma, age, sex,
Idazoxam, motor activity 828
weight and height correlates 503-512 Ifenprodil 186, 232, 233
5-Hydroxytryptamine Imipramine
animal model of anxiety 209, 748, 750 effect on 5-HT induced PI response 379, 401
depletion and apomorphine or amphetamine interhemispheric asymmetry in binding in human
induced behaviours 105-117 brain 760
depression post-psychotic depression, TRH test 373, 374
animal model 735-744 prophylactic efficacy 71-82
interhemispheric asymmetry in human schizophrenia 3, 4
brain 759-764 substance abuse 8
a-methyltryptophan as a therapeutic agent 935 seasonal platelet binding in depression 25-39
phosphoinositide hydrolysis in platelets, thyroid hormone changes in panic disorder 598
depression 49-61
Immunogenetic disease 177
phosphoinositide response in hippocampus, effect Inborn errors of metabolism, genetic
of antidepressants 393-403 databases 171-181
pineal, clorgyline and age 897 Indoleacetic acid, plasma, age, sex, weight and
role in HPA axis escape from dexamethasone height correlates 503-512
suppression 637-642 Infantile autism, magnetic resonance imaging 586
seasonal platelet uptake in depression 25-39 Infant separation, test for anxiolytics 745-757
turnover in brain, effect of SCH 23390 and Information processing
ritanserin 861-872 clonidine and scopolamine 497-502
5-Hydroxytryptamine 1A receptors depression 249
antidepressants 740 Inositol monophosphate, 5-HT induced
anxiety, animal model 748, 750 accumulation in platelets in
anxiety disorders and depression 723-733 depression 49-61
candidate loci, schizophrenia 176 Integrated genetic databases 171-181
5-Hydroxytryptamine 1A receptor agonists, Interleukin-1
anxiolytic potential 209 Alzheimer’s disease 490
5-Hydroxytryptamine 1B receptors, animal model internalization in pituitary cells 553, 557
of anxiety 749, 750 potentiation of B-endorphin secretion 551-560
5-Hydroxytryptamine 1C receptor antagonists, Interleukin-6 482
migraine 194 Alzheimer’s disease 490
5-Hydroxytryptamine 1D receptors, migraine 191 neurite outgrowth and neuronal viability 486
5-Hydroxytryptamine 2 receptors production by stimulated astrocytes 483, 485
dopamine turnover 861-872
Iprindole, effect on 5-HT induced PI
platelets, depresssion 49-61 response 397, 401
5-Hydroxytryptamine 2 receptor antagonists, Ipsapirone, response in anxiety disorders and
migraine 193 depression 725, 726
5-Hydroxytryptamine 3 receptor antagonists,
migraine 194
5-Hydroxytryptophan
animal model of depression 738 Kainate receptors, modulation of cerebellar
melatonin synthesis and aging 561-566 cGMP 230
Hyperthermia, amphetamine induced 841-850
Hypothalamic phospholipid liposomes, reduction of
lithium side effects 428 Language skills, Alzheimer’s disease 446
Hypothalamus Lateralization
eating disorders 351 anorexia nervosa 15-21
ontogeny of cholecystokinin induced modulation 5-HT in human brain 759-764
of food intake 406, 410 Learning, dietary choline in aging rats 677-688
Hypothalamus-pituitary—adrenal axis Leukocytes, depression, B-adrenoceptors and
alcoholism 771, 776 amineptine treatment 357-367
response to D-fenfluramine in depressed Light
patients 781-790 melatonin synthesis, effect of aging 561-566
role of 5-HT in escape from dexamethasone sensitivity in bipolar affective disorder, lithium
suppression 637-642 administration by eye drops 315-321
Hypomotility, apomorphine induced 692, 694 Limbic dysfunction, model of depression 200, 202
xvi Subject Index
Lithium NMDA receptor binding 184
administration by eye drops 315-321 Monkey
forskolin binding in brain 709-716 behavioural effects of CRH 379-391
induced malignant syndrome 428-430 dopamine D2 receptor mRNA in brain 885-893
prophylactic efficacy 79 Monoamine oxidase
Locomotion deamination of 2-propyl-1-aminopentane and
amphetamine and apomorphine induced changes, 2-((2-propyl)pentylamino)
effect of 5-HT depletion 105-117 acetamide 303-306
animal model of attention deficit hyperactivity methylated phenelzine 309
disorder 129 paranoid schizophrenics 45
ethanol-induced decrement, effect of ganglioside Monoamine oxidase inhibitors
and sialic acid 91-104 effect on dopamine and phenylethylamine in
low-dose apomorphine 691 brain 146
muscarinic receptors in basal forebrain 279-284 peripheral 297-301
pineal melatonin synthesis, aging 895-902
Monoamines, acidic metabolites in
Magnetic resonance imaging 581-593 plasma 503-512
affective disorder 584, 585 Mood, anorexia nervosa 15-23
dementia 586 Motor activity
infantile autism 586 dopaminergic agents, scaling approach 903-919
neurotic disorders 587 a-noradrenergic system 825-840
pituitary abnormalities in eating Motor skills, Alzheimer’s disease 461
disorders 351-356 Multi-infarct dementia, glycosaminoglycan
schizophrenia 584, 585 polysulfate 323-342
Malignant hyperthermia, psychotropic drugs 427 Muscarinic-nicotinic mechanisms 539-549
Mandelic acid, in plasma, age, sex, weight and Muscarinic receptors, basal forebrain,
height correlates 503-512 locomotion 279-284
Mania, magnetic resonance imaging 588
MDL 72222, migraine 194
Mecamylamine, augmentation of hypothermic Naloxone
response to oxotremorine 542 inhibition of amphetamine-induced loss of
Melatonin prepulse inhibition 420
clorgyline-induced synthesis, aging 895-902 visual evoked potentials 567-579
5-HTP, light and aging 561-566 Narcolepsy 177
Memory Neostriatum, nerve growth factor 157-169
aging 435 Nerve growth factor 851
Alzheimer’s disease 453 Alzheimer’s disease 858
arecoline 643-648 cholinergic function in hippocampus 853
clonidine and scopolamine 497 clinical implications 163
HIV positive drug abusers 655 distribution and binding sites in
Methadone, HIV positive abusers, neostriatum 158
SPECT 649-662 injury 161
Methamphetamine, antagonism by SCH 23390 and neuronal transport 160
raclopride 803-815 ontogenetic changes 161
N-Methyl-D-aspartate receptor Nerve growth factor receptors 159
animal model of anxiety 750 Neuroleptic Malignant Syndrome 427
glutamate, glycine and polyamines 183-190 Neuroleptics
modulation of cerebellar cGMP 230 schizophrenia 221-228
regulation of dopamine release from nucleus blood levels 225
accumbens 663-676 dosage strategies 223
Methylation, phenelzine 307-312 side effects 222
Methylatropine, antagonism of physostigmine verapamil interaction 343-349
effects 875 supersensitivity, diltiazem 717-722
Methylephedrine, in BRON 513-521 Neurons, interleukin-6 486
DL-threo-Methylphenidate, metabolism in Neuropsychological testing, HIV-positive drug
humans 213-220 abusers 649-662
Methyltestosterone, growth hormone response to Neurotensin, sensitive protein
apomorphine 263-268 phosphorylation 83-89
a-Methyltryptophan, therapeutic agent 935-938 Nicotine, hypothermic effect, amitriptyline-induced
Metoclopromide, migraine 194 supersensitivity 540, 545
Migraine, 5-HT receptors 191-197 Nitric oxide, modulation of cGMP by excitatory
MK-801 amino acids 231
dopamine release from nucleus accumbens 668 Noradrenaline, motor activity 826
Subject Index
Nortriptyline in plasma
prophylactic efficacy 71-82 age, sex, weight and height
simulated home treatment of depression 63-70 correlates 503-512
Nucleus accumbens effect of dietary phenylalanine 611-623
dopamine D1 receptor mediated inhibition Phenylalanine
of neurons from ventral tegmental cholecystokinin satiety ontogeny in rats 405-413
area 119-128 dietary, plasma phenylalanine, phenylethylamine
dopamine release and NUDA and phenylacetic acid 611-623
receptors 663-673 Phenylethanolamine N-methyltransferase,
phenelzine methylation 307-312
Phenylethylamine
Obsessive-compulsive disorder, 5-HT, 4 analysis 140
receptors 730 dietary phenylalanine 611-623
Olfactory bulbectomy, model of depression 202 distribution and metabolism 142
Online Mendelian Inheritance in Man 173 electrophysiological effects 149
Ontogeny, cholecystokinin satiety in marker in neuropsychiatric disorders 143
undernourished rats 405-413 MAO effects 146
Open field, dietary choline and behaviour 679, modulation of catecholaminergic
83, 684 neurotransmission 139-156
Opiate, dopamine interactions in acoustic startle neuromodulator in dopaminergic
reflex 415-426 neurotransmission 45
Opiate dependence, buprenorphine 531-538 urinary, paranoid schizophrenia 44
Opioid peptides, visual processing 567-579 Phosphoinositide
Optic chiasm, naloxone and visual evoked 5-HT stimulated hydrolysis in hippocampus,
potentials 570 effect of antidepressants 393-403
Oral stereotypies, quinpirole-induced, effect of 5-HT stimulated hydrolysis in platelets in
diltiazem 717-722 depression 49-61
Orthostatic hypotension, nortriptyline 64, 66, 68 Photosensitivity, bipolar affective disorder 315
Over-the-counter cough suppressant, abuse Physostigmine, hypothermic and neuroendocrine
of 513-521 responses, antagonism 873-884
Oxotremorine, hypothermic effect, mecamylamine Pindolol, heart rate 702, 704
sensitivity 541, 542 Pineal gland, melatonin response to clorgyline,
aging 895-902
Pirenzepine, carbachol and locomotion 283
P300 761 Pituitary cells, interleukin-1 potentiation of
Panic disorder endorphin secretion 551-560
cholecystokinin and carbon dioxide 237-239 Pituitary gland, eating disorders 351-356
5-HT;, receptors 728 Platelets
sodium divalproex—benzodiazepine 5-HT, function in depression 49-61
interaction 269-273 seasonal 5-HT uptake and imipramine binding in
thyroid hormones during treatment 595-600 depression 25-39
Paranoid schizophrenia Polyamines
phenylacetic acid in CSF and serum 41-47 cerebellar CGMP 233
phenylacetic acid and phenylethylamine in modulation of NMDA receptor 184
brain 143 Postmortem brain, serotonergic interhemispherical
Parkinson’s disease, phenylethylamine and asymmetry 759-764
catecholaminergic neurotransmission 152 Post-psychotic depression, thyroid releasing
Pentobarbital, hypothermic effect, amphetamine hormone test 369-378
conditioning 846 Potassium, dopamine release from nucleus
Peptide T, AIDS 791-801 accumbens 667, 672
Perceptual function, Alzheimer’s disease 459 Practice, psychometric testing 625-635
Pharmaco-EEG, serotonergic interhemispheric Praxis, Alzheimer’s disease 461
asymmetry 759-764 Prazosin, motor activity 835
Phencyclidine, NMDA receptor in Prepulse inhibition, acoustic startle 415, 419
schizophrenia 184 Primary degenerative dementia
Pheneizine early detection battery 433-479
MAO inhibition 297-301 glycosaminoglycan polysulfate 323-342
methylation 307-312 Problem solving, Alzheimer’s disease 465
Phenolsulfotransferase, platelets, Procyclidine, antagonism of physostigmine
depression 241-247 effects 875
Phenylacetic acid Prodrug, valproic acid 304
in CSF and serum in schizophrenia 41-47 Proglumide, reversal of hypnotic action of
marker in neuropsychiatric disorders 143 flunitrazepam 817-823
xviii Subject Index
Prolactin, response to D-fenfluramine in thyroid releasing hormone test in post-psychotic
depression 786 depression 369-378
Prophylactic efficacy, tricyclic verapamil 343-349
antidepressants 71-82 Scopolamine
Propranolol, heart rate 702, 705 antagonism of physostigmine effects 875
2-Propyl-1-aminopentane, deamination and information processing 497-502
anticonvulsant activity 303-306 Seasonal variation, platelet 5-HT uptake in
2-((Propyl)pentylamino)acetamide, deamination depression 25-39
and anticonvulsant activity 303-306 Semicarbazide-sensitive amine oxidase 303-306
Protein, neurotensin-sensitive Senile dementia, early detection battery 433-479
phosphorylation 83-89 Sensitization, amphetamine 842, 847
Protein kinase C, depletion and interleukin-1 Sensorimotor gating, opiate-dopamine
potentiation of B-endorphin secretion 554, interaction 416, 422
597, Sensory modulation, naloxone 568, 573
Psychometric testing, practice effect 625-635 Separation
Psychomotor retardation, depression 249, 257 animal model of depression 201
Psychotic depression, tricyclic test for anxiolytics 745-757
antidepressants 765-770 Serotonergic agents, migraine 191-197
Punishment, anxiolytic drugs 207 Sex differences
CSF cholecystokinin in schizophrenics 604
monoamine metabolites in plasma 506
Quinpirole serotonergic lateralization 761
induced oral stereotypies, effect of Sialic acid, attenuation of intoxicating effects of
diltiazem 717-722 ethanol 91-104
motor activity 909, 914 SKF 38393
Quisqualate receptors, modulation of cerebellar motor activity 909, 914
cGMP 230 nucleus accumbens neurons 122-126
Sleep
ethanol and ganglioside 95
Raclopride, methamphetamine flunitrazepam and proglumide 817-823
antagonism 803-815 Slow release, methylphenidate 220
Rat strains, somatic and behavioural ontogeny and ~ Sodium divalproex, benzodiazepine
dopamine D1 receptors 129-138 interaction 269-273
Reaction time Spatial scaling component, dopamine and motor
clonidine and scopolamine 499 behaviour 914
depression 249, 257 Species differences
Red blood cells, haloperidol reductase 275-278 antidepressant metabolism 285
Ritanserin, effect on dopamine and 5-HT turnover cholecystokinin receptors in brain 291
in brain 861-872 corticotropin releasing hormone 386
RO 15-1788, animal model of anxiety 748 SPECT scanning, HIV-positive drug
Ro 15-4513, binding to GABA receptors during abusers 649-662
ethanol withdrawal 924 Spermidine, NMDA receptor 185
Stereotypy, apomorphine 693
Stress
SCH 23390 animal models of depression 201
effect on dopamine and 5-HT turnover in beta-blockers, diazepam and heart rate 699-708
brain 861-872 induced hyperthermia 848
methamphetamine antagonism 803-815 Stroke, NMDA receptor 184
effect on nucleus accumbens neurons 122-126 Substance abuse
ontogeny of dopamine D1 receptor 134 BRON 513-521
Schizophrenia HIV, SPECT 649-662
antidepressants and substance abuse 1-13 schizophrenics, antidepressants 6-9
candidate serotonergic gene 176 Sumatriptan, migraine 192
cholecystokinin in CSF 601-609 Suriclone, anxiolytic properties 207
genetic databases 173
haloperidol reductase in red blood
cells 275-278 Tardive dyskinesia
magnetic resonance imaging 584, 585 diltiazem 717-722
neuroleptics 221-228 neuroleptics 223
NMDA receptor 184 verapamil 343-349
phenylacetic acid in CSF and serum 41-47 Temporal discrimination, dietary choline 679,
phenylacetic acid and phenylethylamine in 681, 684
brain 143, 152 Tetrabenazine, animal model of depression 736
Subject Index
Thermoregulation Valproic acid
muscarinic-nicotinic mechanisms 539-549 formation from
physostigmine 873-884 2-((2-propyl)pentylamino)acetamide and
Thyrotropin releasing hormone test, post-psychotic 2-propyl-l-aminopentane 304
depression 369-378 Vanillylmandelic acid, in plasma, age, sex, weight
Thyroxine, changes during treatment of panic and height correlates 503-512
disorder 595-600 Vasopressin, induced B-endorphin release,
Tourette syndrome, genetic databases 173 interleukin-1 potentiation of 554, 557
Transducin, lithium interaction with G Ventral tegmental area, dopamine D1 receptor
proteins 317, 318 mediated inhibition of nucleus accumbens
Tranylcypromine, forskolin binding in neurons 119-128
brain 709-716 Verapamil, schizophrenia 343-349
Trazodone, schizophrenia 3 Verbal memory
Tricyclic antidepressants Alzheimer’s disease 453
induced malignant syndrome 427 arecoline 643-648
metabolism in rat 285-289 HIV-positive drug abusers 653, 655
orthostatic hypotension 64, 66, 68 Visual evoked potentials, naloxone 567-579
prophylactic efficacy 71-82 Visuospatial deficits, Alzheimer’s disease 457
psychotic depression 765-770 Visuospatial function, arecoline 643-648
schizophrenia 3 Vocabulary, dementia 446
simulated home treatment of depression 63-70
Trimipramine, metabolism in rat 285-289
Tryptophan hydroxylase, inhibition and evoked
behaviours 105-117
Weight, monoamine metabolites in plasma 508
p-Tyramine challenge test, depression 241-247 Withdrawal, ethanol, GABA 921-934
Word fluency, Alzheimer’s disease 448
Ultrasonic vocalization, test for
anxiolytics 745-757
Undernutrition, cholecystokinin and food
intake 405-413 Yawning, apomorphine-induced 692